 | Up a level |
Number of items: 1.
Lin, C. C., Joerger, M., Grell, P., Chiappori, A. A., Leal, T. A., Kasper, S., Jerusalem, G., Goncalves, A., Wolf, J., De Braud, F., de Jonge, M. J. A., Otero, J., Chhagan, S., Cipolletta, D., Morris, E., Chowdhury, N. R., Hurtado, F. K. and Tan, D. S. (2020). Continuous vs intermittent adenosine 2A receptor (A2AR) inhibition in preclinical colon cancer (CC) models and in a Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients ( pts) with non-small cell lung cancer (NSCLC). Eur. J. Cancer, 138. S. S12 - 2. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852